Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

30 Oct 2020

Abstract excerpt

Abstract Detecting persistent minimal residual disease (MRD) allows the identification of patients with an increased risk of relapse and death. In this study, we have evaluated MRD 3 months after transplantation in 106 myeloma patients using a commercial next-generation sequencing (NGS) strategy (LymphoTrack®), and compared the results with next-generation flow (NGF, EuroFlow). The use of different marrow pulls...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33127891
DOI: 10.1038/s41408-020-00377-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myelomaPMID 33127891Read ↗

Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic useSemantic proximity Read ↗

Monitoring minimal residual disease in the bone marrow using next generation sequencing.Semantic proximity Read ↗

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future PerspectivesSemantic proximity Read ↗

Applications of Multiparameter Flow Cytometry in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma PatientsSemantic proximity Read ↗

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment.Semantic proximity Read ↗

Cell-free DNA Whole Genome Sequencing for Non-Invasive Minimal Residual Disease Detection in Multiple MyelomaSemantic proximity Read ↗

Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myelomaSemantic proximity Read ↗

Establishing Measurable Residual Disease Trajectories for Patients on Treatment for Newly Diagnosed Multiple Myeloma as Benchmark for Deployment of T-cell Redirection TherapySemantic proximity Read ↗

Molecular detection of minimal residual disease in multiple myelomaSemantic proximity Read ↗

Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological MalignanciesSemantic proximity Read ↗

Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patientsSemantic proximity Read ↗

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.